{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:30:22Z","timestamp":1789576222469,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upadacitinib, a specific JAK1 inhibitor, has minimal effect on other JAK subtypes. It influences the inflammatory process in various ways. Upadacitinib has been approved for conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis in various countries. The purpose of this study is to assess the clinical efficacy and safety of upadacitinib in patients with refractory palmoplantar pustulosis who have not responded to conventional treatments (e.g., Acitretin, Tripterygium wilfordii Hook F, cyclosporine, methotrexate).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective collection of clinical data from 28 patients who received upadacitinib treatment at the Department of Dermatology, First Affiliated Hospital of Suzhou University, from July 2022 to December 2023. We evaluated the Palmoplantar Pustulosis Area and Severity Index (PPPASI) scores, Dermatology Life Quality Index (DLQI) scores, and Physician\u2019s Global Assessment (PGA) scores before and after treatment. We also recorded any adverse events during the treatment process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 28 patients were diagnosed with PPP, including 10 males and 18 females, and 8 patients (3 males and 5 females) were diagnosed with SAPHO syndrome. The mean age was (36.3\u2009\u00b1\u200910.5) years. After 12\u2009weeks of treatment, PPPASI scores decreased from baseline (13.86\u2009\u00b1\u20092.76) to (5.56\u2009\u00b1\u20091.08), with a statistically significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). DLQI scores decreased from (12.55\u2009\u00b1\u20094.56) to (2.03\u2009\u00b1\u20091.13), also showing a statistically significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05). Additionally, 20 patients achieved a PGA score of 0\/1. No severe adverse events were reported during the treatment and follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upadacitinib could be an additional safe and effective treatment for treating refractory palmoplantar pustulosis with a potential benefit on patients\u2019 quality of life. Further studies are needed to assess its short-and long-term efficacy and safety in larger sample sizes in randomized double-blind controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1476793","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:14:38Z","timestamp":1730852078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients"],"prefix":"10.3389","volume":"11","author":[{"given":"Na","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1111\/jdv.14187","article-title":"Quality of life and comorbidities in palmoplantar pustulosis \u2013 a cross-sectional study on 102 patients","volume":"31","author":"Trattner","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2019.1708194","article-title":"The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review","volume":"16","author":"Kharawala","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","first-page":"931","volume-title":"Chinese clinical dermatology. Version 2","author":"Bian","year":"2017"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.35541\/cjd.20210698","article-title":"Chinese Expert Consensus on Diagnosis and Treatment of Imstular Psoriasis (2022 edition)","volume":"55","author":"Yuling","year":"2022","journal-title":"Chinese J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamadermatol.2020.3275","article-title":"Association of clinical and demographic factors with the severity of palmoplantar pustulosis","volume":"156","author":"Benzian-Olsson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","article-title":"Efficacy and safety of guselkumab, an anti \u2043 interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial [J]","volume":"155","author":"Terui","year":"2019","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e006450","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota","year":"2015","journal-title":"BMJ Open"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40257-023-00807-2","article-title":"General characteristics and comorbidities in patients with palmoplantar pustulosis","volume":"24","author":"Misiak-Galazka","year":"2018","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/1346-8138.13751","article-title":"Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal","volume":"44","author":"Kouno","year":"2017","journal-title":"J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/14651858","article-title":"Interventions for chronic palmoplantar pustulosis","volume":"15","author":"Pennington","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/jid.2015.186","article-title":"Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients","volume":"135","author":"M\u00f6ssner","year":"2015","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: current understanding of disease defifinition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J Dermatol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"eaan 2514","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci Transl Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J Dermatol Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3892\/mmr.2020.11052","article-title":"Therapeutic targets of thunder god vine (Tripterygium wilfordii hook) in rheumatoid arthritis (review)","volume":"21","author":"Song","year":"2020","journal-title":"Molecul Med Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bjps.2021.05.074","article-title":"Medicines and healthcare products regulatory agency","volume":"75","author":"Zargaran","year":"2022","journal-title":"Aesthet Surg."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2125.2012.04221.x","article-title":"Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases: triptolide for inflammatory diseases","volume":"74","author":"Han","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2623085","article-title":"Efficacy and safety of tripterygium wilfordii hook F on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials","volume":"2018","author":"Lv","year":"2018","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fphar.2016.00402","article-title":"Safety profiles of tripterygium wilfordii hook F: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J Invest Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clim.2016.10.003","article-title":"Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: impact of this JAK inhibitor on T-cell differentiation","volume":"173","author":"Koga","year":"2016","journal-title":"Clin Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/ddg.14969","article-title":"Response of palmoplantar pustulosis to upadacitinib","volume":"21","author":"Mohr","year":"2023","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1476793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:14:40Z","timestamp":1730852080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1476793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":27,"alternative-id":["10.3389\/fmed.2024.1476793"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1476793","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"article-number":"1476793"}}